文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

克服乳腺癌耐药性的最新策略。

Recent strategies to overcome breast cancer resistance.

机构信息

Center of Nanomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA.

出版信息

Crit Rev Oncol Hematol. 2024 May;197:104351. doi: 10.1016/j.critrevonc.2024.104351. Epub 2024 Apr 12.


DOI:10.1016/j.critrevonc.2024.104351
PMID:38615873
Abstract

Breast cancer is potentially a lethal disease and a leading cause of death in women. Chemotherapy and radiotherapy are the most frequently used treatment options. Drug resistance in advanced breast cancer limits the therapeutic output of treatment. The leading cause of resistance in breast cancer is endocrine and hormonal imbalance, particularly in triple negative and HER2 positive breast cancers. The efflux of drugs due to p-gp's activity is another leading cause of resistance. Breast cancer resistant protein also contributes significantly. Strategies used to combat resistance include the use of nanoparticles to target drug delivery by co-delivery of chemotherapeutic drugs and genes (siRNA and miRNA) that help to down-regulate genes causing resistance. The siRNA is specific and effectively silences p-gp and other proteins causing resistance. The use of chemosensitizers is also effective in overcoming resistance. Chemo-sensitizers sensitize cancer cells to the effects of chemotherapeutic drugs. Novel anti-neoplastic agents such as antibody-drug conjugates and mesenchymal stem cells are also effective tools used to improve the therapeutic response in breast cancer. Similarly, combination of photo/thermal ablation with chemotherapy can act to overcome breast cancer resistance. In this review, we focus on the mechanism of breast cancer resistance and the nanoparticle-based strategies used to combat resistance in breast cancer.

摘要

乳腺癌是一种潜在的致命疾病,也是女性死亡的主要原因。化疗和放疗是最常用的治疗方法。晚期乳腺癌的药物耐药性限制了治疗的疗效。乳腺癌耐药的主要原因是内分泌和激素失衡,特别是在三阴性和 HER2 阳性乳腺癌中。由于 p-糖蛋白的活性导致药物外排也是耐药的另一个主要原因。乳腺癌耐药蛋白也有很大的贡献。用于对抗耐药性的策略包括使用纳米颗粒通过共递送化疗药物和基因(siRNA 和 miRNA)来靶向药物递送,这些基因有助于下调导致耐药性的基因。siRNA 是特异性的,可有效沉默 p-糖蛋白和其他导致耐药性的蛋白。使用化疗增敏剂也能有效地克服耐药性。化疗增敏剂使癌细胞对化疗药物的作用敏感。新型抗肿瘤药物,如抗体药物偶联物和间充质干细胞,也是用于提高乳腺癌治疗反应的有效工具。同样,将光/热消融与化疗相结合可以克服乳腺癌的耐药性。在这篇综述中,我们重点介绍了乳腺癌耐药的机制以及基于纳米颗粒的策略,用于对抗乳腺癌的耐药性。

相似文献

[1]
Recent strategies to overcome breast cancer resistance.

Crit Rev Oncol Hematol. 2024-5

[2]
A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.

Acta Biomater. 2018-6-3

[3]
Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.

Enzymes. 2018

[4]
Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.

Int J Clin Exp Pathol. 2014-3-15

[5]
Nano-Based Drug Delivery of Anticancer Chemotherapeutic Drugs Targeting Breast Cancer.

Recent Pat Anticancer Drug Discov. 2023

[6]
Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.

Int J Mol Sci. 2021-4-28

[7]
Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers.

Adv Exp Med Biol. 2021

[8]
Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.

J Control Release. 2014-11-15

[9]
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.

Drug Resist Updat. 2020-5

[10]
A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.

Breast Cancer Res Treat. 2017-7-12

引用本文的文献

[1]
Ferroptosis as a Therapeutic Avenue in Triple-Negative Breast Cancer: Mechanistic Insights and Prognostic Potential.

Biomedicines. 2025-8-21

[2]
Synergistic Antitumor Effects of Ivermectin and Metformin in Canine Breast Cancer via PI3K/AKT/mTOR Pathway Inhibition.

Curr Issues Mol Biol. 2025-5-29

[3]
Synergistic antitumor effects and mechanistic insight of hypericin-mediated photodynamic therapy combined with Olaparib in MCF-7 BRCA1 wild-type breast cancer cells.

Med Oncol. 2025-7-9

[4]
Deciphering Radiotherapy Resistance: A Proteomic Perspective.

Proteomes. 2025-6-16

[5]
Multifaced Anticancer Potential of Doxorubicin: Spotlight on Breast Cancer.

Dis Res. 2025-3

[6]
PARP-1 as a novel target in endocrine-resistant breast cancer.

J Exp Clin Cancer Res. 2025-6-16

[7]
Identification and validation of prognostic genes associated with T-cell exhaustion and macrophage polarization in breast cancer.

Front Endocrinol (Lausanne). 2025-5-27

[8]
Mechanisms and potential therapeutic strategies of withaferin A in breast cancer.

Pharmacol Rep. 2025-5-20

[9]
YX-112, a novel celastrol-derived PROTAC, inhibits the development of triple-negative breast cancer by targeting the degradation of multiple proteins.

Front Pharmacol. 2025-4-15

[10]
Exploring the Potential of Mitochondria-Targeted Drug Delivery for Enhanced Breast Cancer Therapy.

Int J Breast Cancer. 2025-3-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索